[1] |
ZHANG Yujia, MA Li.
Advances and controversies in new techniques of breast pathology
[J]. China Oncology, 2025, 35(3): 283-290.
|
[2] |
WANG Haochen, JIA Liqing, YANG Yu, WANG Qian, YU Chengli, TIAN Tian, BI Rui, TU Xiaoyu, BAI Qianming, ZHU Xiaoli, ZHOU Xiaoyan, REN Min.
A study on the correlation between HPV DNA and IHC P16 expression in cervical lesions
[J]. China Oncology, 2025, 35(3): 298-308.
|
[3] |
WANG Qing, YU Yushuai, WANG Chenxi, JIANG Zirong, LI Jialu, TANG Shicong, SONG Chuangui.
Current status and prospects of tertiary lymphoid structure heterogeneity in predicting response to neoadjuvant therapy and characterizing immune microenvironment in triple-negative breast cancer
[J]. China Oncology, 2025, 35(2): 213-218.
|
[4] |
CAO Xiaoshan, YANG Beibei, CONG Binbin, LIU Hong.
The progress of treatment for brain metastases of triple-negative breast cancer
[J]. China Oncology, 2024, 34(8): 777-784.
|
[5] |
Expert Committee on Pathology of Chinese Research Hospital Association , Professional Committee on Tumor Pathology of Shanghai Anticancer Association .
Practice guideline for the histopathological diagnosis of mesothelioma (2025 version)
[J]. China Oncology, 2024, 34(12): 1144-1163.
|
[6] |
CHEN Lijun, WANG Yichen, ZHENG Qiang, WANG Yue, JIN Yan, LI Yuan.
Consistency analysis of PD-L1 immunohistochemistry antibodies in esophageal squamous cell carcinoma
[J]. China Oncology, 2023, 33(5): 469-477.
|
[7] |
CHEN Junyao, ZHANG Wentao, LIU Qiao, NIE Jianyun.
Clinical dilemma and systemic treatment strategy of triple-negative breast cancer in the elderly
[J]. China Oncology, 2023, 33(5): 506-516.
|
[8] |
CD-Positive Lymphoma Pathology Expert Group.
The standardization of immunohistochemical detection and interpretation of CD30 expression in lymphomas
[J]. China Oncology, 2023, 33(3): 228-234.
|
[9] |
SHAO Zhibo, YANG Benlong, WU Jiong.
Progress of important clinical trials of breast cancer in China in 2022
[J]. China Oncology, 2023, 33(2): 103-109.
|
[10] |
SHEN Jie, LIU Yajing, MO Miao, ZHOU Jin, WANG Zezhou, ZHOU Changming, ZHOU Shichong, CHANG Cai, ZHENG Ying.
Effectiveness of artificial intelligence-assisted ultrasound for breast cancer screening in Chinese women
[J]. China Oncology, 2023, 33(11): 1002-1008.
|
[11] |
XIAO Yuling, ZHU Xiuzhi, JIANG Yizhou, SHAO Zhimin.
New research advances and future prospect in precision treatment of triple-negative breast cancer
[J]. China Oncology, 2022, 32(8): 669-679.
|
[12] |
QU Yiping, HOU Peng.
Genetic characteristics and prognosis of metastatic thyroid cancer in children
[J]. China Oncology, 2022, 32(5): 373-379.
|
[13] |
WU Quan, GUO Jingwei, LEI Yuxin, HU Xiaoru, WANG Zhe.
Expression of MMR in 515 cases of endometrioid adenocarcinoma and its correlation with clinicopathological features
[J]. China Oncology, 2022, 32(12): 1190-1198.
|
[14] |
GUO Jingjing, TANG Xiubin, CHEN Lei, QIAN Qingfu, LIN Liwu, XUE Ensheng, CHEN Zhikui.
Application value of decision tree model based on ultrasonic signs in predicting the risk grade of gastrointestinal stromal tumors
[J]. China Oncology, 2022, 32(1): 41-46.
|
[15] |
XU Ran , WANG Xinyue , FENG Linyuan , HAN Anna , WANG Yixuan , YANG Wanshan , LIU Chao .
Expression and biological significance of NCAPD2 in glioma
[J]. China Oncology, 2021, 31(9): 789-798.
|